Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of current ratings and target prices for Prelude Therapeutics and Pyxis Oncology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prelude Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Pyxis Oncology | 1 | 0 | 7 | 0 | 2.75 |
Prelude Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 121.24%. Pyxis Oncology has a consensus target price of $9.00, suggesting a potential upside of 437.31%. Given Pyxis Oncology’s stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than Prelude Therapeutics.
Institutional & Insider Ownership
79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 10.5% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Prelude Therapeutics and Pyxis Oncology”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prelude Therapeutics | $12.14 million | 26.00 | -$99.50 million | ($0.73) | -5.42 |
| Pyxis Oncology | $13.86 million | 10.08 | -$79.62 million | ($1.41) | -1.19 |
Pyxis Oncology has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Prelude Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
Profitability
This table compares Prelude Therapeutics and Pyxis Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prelude Therapeutics | N/A | -75.35% | -44.39% |
| Pyxis Oncology | N/A | -215.23% | -112.19% |
Summary
Pyxis Oncology beats Prelude Therapeutics on 7 of the 13 factors compared between the two stocks.
About Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
About Pyxis Oncology
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
